Nursing Medical News about Dipeptidyl-Peptidase IV Inhibitors

Become a Member Today!
Register

Most Viewed Abstracts

1. Report Shows Shift in Starting Salaries for Physicians

2. Recommendations on the use of 18F-FDG PET in oncology

3. Use of Antiemetic Agents in Acute Gastroenteritis

4. Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer

5. AHA Guidelines on Cardiac CT for Assessing Coronary Artery Disease

Your Article Summary

See Latest Articles

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Dipeptidyl peptidase inhibitors, an emerging drug class for inflammatory disease?
Trends in Pharmacological Sciences, 11/06/09

Yazbeck R et al. – Dipeptidyl peptidase (DPP)–4 is a member of the S9b serine protease family, which also includes DPP8 and DPP9. DPP4 cleaves a number of regulatory factors, including chemokines and growth factors. DPP4 inhibitors have recently emerged as an effective treatment option for type 2 diabetes. Early in vitro studies demonstrated that DPP4 inhibitors inhibit T–cell proliferation and cytokine production, leading to their investigation in numerous pre–clinical models of inflammatory diseases, including arthritis, multiple sclerosis and inflammatory bowel disease. Recent data suggest that the early DPP4–specific inhibitors might also bind DPP8 and DPP9, thus exerting their effects through non–specific binding. This review highlights recent insights into the applicability of DPP inhibitors as novel pharmacological agents for inflammatory disease.

<< Previous
Topical Pimecrolimus: A Review of its Use in the Management of...

Next >>
Steroid Therapy of Septic Shock

The next ten stories on antiviral drug discovery (part E): Advents, Advances, and Adventures
Medicinal Research Reviews, 10/21/09 Relevance Score: 66%

Molecular mechanism underlying the synergistic interaction between trifluorothymidine and the epidermal growth factor receptor inhibitor erlotinib in human colorectal cancer cell lines
Cancer Science, 11/16/09 Relevance Score: 64%

Gilead Sciences Announces Plans for Phase IV Clinical Trial Evaluating First-Line Combination Therapy Versus Monotherapy in Pulmonary Arterial Hypertension
Gilead, 11/03/09 Relevance Score: 64%

Beyond Glycemic Control: Treating the Entire Type 2 Diabetes Disorder
Postgraduate Medicine, 10/05/09 Relevance Score: 64%

Defining the Importance of Daily Glycemic Control and Implications for Type 2 Diabetes Management
Postgraduate Medicine, 10/05/09 Relevance Score: 64%